[Ip-health] PharmaTimes - India, Mercosur "must withstand EU pharma demands"

Sophie Bloemen Sophie at haieurope.org
Thu May 5 10:59:18 PDT 2011



India, Mercosur "must withstand EU pharma demands"


World News | May 05, 2011


Lynne Taylor


India, Mercosur "must withstand EU pharma demands"


Nations currently negotiating trade deals with the European Union (EU)
have been warned that they must resist European demands which could
threaten access to medicines in emerging and developing countries.


The EU-India Free Trade Agreement (FTA), which has been under discussion
since 2007, is expected to be finalised within the next few months and
will have major implications for access to medicines, not only in India
but also in the many developing countries that rely on Indian-produced
generics, says leading nongovernmental organisation (NGO) Health Action
International (HAI). Also, the EU is holding a new round of negotiations
in Paraguaythis week toward agreeing an Association Agreement with the
Mercosur countries - Argentina, Brazil, Paraguay, Uruguay and Venezuela
- aimed at creating a framework for cooperation.

Related Links

Thousands protest India EU FTA s generic drug provisions Europe US
"using fake drugs crisis to boost pharma profits" EU pledge to India
over generics seizures Fury as trade deals "threaten generics"


There is "widespread concern" that health budgets and access to
medicines throughout the Mercosur region will come under further strain
as a result of this proposed Association Agreement, says HAI.


The NGO emphasises that India's resistance to the EU's "over-reaching"
intellectual property (IP) demands will be "crucial" for the protection
of health and development globally, and adds: "negotiations do not take
place in a vacuum - both India and Mercosur must stand firm to halt the
momentum of the EU's IP creep."


During the EU-India FTA negotiations, the European side has been calling
on India to enforce a stricter IP regime that is provided by its
national legislation and the World Trade Organisation (WTO)'s
Trade-Related Intellectual Property Rights (TRIPs) agreement.
Specifically, the EU has said that India must adopt data exclusivity
provisions, which would prolong the market monopoly period for
brand-name drugs. But doing so would threaten India's position as the
"pharmacy of the developing world," with a generics industry which is
worth more than $20 billion and exports 50% of its production.


However, late last week, Indian Prime Minister Manmohan Singh told his
country's negotiators not to take on any new obligations. Following a
review of the negotiations by the Indian government's Trade and Economic
Relations Committee, at which "it was observed that concern has been
raised by various quarters about the Indian stand" on IP issues,
especially in the context of Indian pharmaceuticals, "the Prime Minister
firmly directed that the Indian side shall not take on any obligation
beyond TRIPs/domestic law," said a statement issued by the Prime
Minister's Office (PMO).


HAI accuses the EU of taking "a simplistic view of IP, based on its
assumptions that the more stringent the IP protection the better. It
fails to consider the adverse effects of high levels of IP protection on
technology transfer, innovation, development and public health for
emerging and developing countries," it says, and calls on Europe instead
to "consider the broader context and effects of its IP demands, not only
for public health but also for socioeconomic development."



More information about the Ip-health mailing list